ClinicalTrials.gg
Sign In

Lung Diseases, Interstitial clinical trials

The registry lists 680 studies for Lung Diseases, Interstitial across more than 10 countries. 246 are recruiting or about to start. 333 of them are mainly about Lung Diseases, Interstitial (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 9 narrower conditions too, such as Idiopathic Pulmonary Fibrosis: 1,658 studies, 460 open.

ClinicalTrials.gov finds 1,776 studies for Lung Diseases, Interstitial. How that becomes 679 here

This page counts the studies the registry files under Lung Diseases, Interstitial, and those it files under no condition that list Lung Diseases, Interstitialthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,776Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −962Filed under a narrower condition, counted on its own pageIdiopathic Pulmonary Fibrosis 469 · Pulmonary Fibrosis 183 · Granulomatosis with Polyangiitis 102 · Histiocytosis, Langerhans-Cell 80 · Sarcoidosis, Pulmonary 54 · Radiation Pneumonitis 35 · 3 more
  3. −16List Lung Diseases, Interstitial as a condition, but the registry did not file them under itMost often written as “Diffuse Interstitial Lung Disease” (2), “Interstitial Lung Disease Due to Systemic Disease” (2), and “Pneumonia, Interstitial Plasma Cell” (1). The registry filed them under other conditions only, most often Lung Diseases (3) and Pulmonary Arterial Hypertension (3).
  4. −121Match it another way49 name it in the title, 2 in a keyword, and 70 by a synonym or other text the search reads.
  5. 677Counted here and found by its search38 of them list Lung Diseases, Interstitial in their own words; the registry filed them under no condition.
  6. +2
    Counted here, but its search does not find them
  7. 679The count on this page

Get an email when these change. Save the Lung Diseases, Interstitial studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
250
Recruiting
174
Status unknown
96
Not yet recruiting
59
Active, not recruiting
39
Terminated
38

Phase

Phase 2
110
Phase 3
66
Phase 1
35
Phase 4
28
Early Phase 1
4

Where

United States
201
United Kingdom
91
France
90
China
76
Germany
66
Canada
64

Who runs them

Boehringer Ingelheim (24) · Assiut University (18) · Assistance Publique - Hôpitaux de Paris (12) · United Therapeutics (8) · Post Graduate Institute of Medical Education and Research, Chandigarh (8) · Duke University (7) · Mayo Clinic (7) · Celgene (7)

What is being tested here

Drugs under test in Lung Diseases, Interstitial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Nerandomilast446
Belimumab434
Treprostinil3710
Treprostinil hexadecyl ester345
Mosliciguat213
Dexamethasone213
Hydroxychloroquine203
CBP-8 gallium GA-68202
Pirfenidone1010
Nintedanib1710

Drug classes tested here Corticosteroids 4 open · Tyrosine kinase inhibitors (TKIs) 2 open · JAK inhibitors 2 open · Alkylating agents 1 open · Endothelin receptor antagonists 7

Coming up

24phase 3 studies under way
83studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 174 Lung Diseases, Interstitial studies recruiting now, 109 (63%) set no upper age limit and 26 (15%) stop at 75 or younger. 13 (7%) take children under 18. 0 (0%) are for women only and 1 (1%) for men only; 22 (13%) take healthy volunteers.

Recruiting studies that take each age, of 174
AgeWomenMen
1012 (7%)12 (7%)
18149 (86%)149 (86%)
30154 (89%)154 (89%)
40169 (97%)169 (97%)
50170 (98%)171 (98%)
65166 (95%)167 (96%)
75162 (93%)163 (94%)
85130 (75%)131 (75%)

Across all 680 studies, recruiting or not: 16% stop at 75 or younger and 5% at 65; 10% take children; <1% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lung Diseases, Interstitial studies take

Of 53 phase 2 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 48 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 248 mo30–71 · 53 studies——
Phase 333 mo29–61 · 36 studies——
Interventional, no phase27 mo14–44 · 118 studies—27 mo14–46 · 114 studies
Observational55 mo31–83 · 132 studies—72 mo35–274 · 111 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting2

Results posted2

Stopped1

Newly registered3

Studies

Recruiting first, then most recently updated. Showing 50 of 680. Browse all 680 → or search them.